After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.

Neuronetics’ NeuroStar Advanced Therapy for Mental Health is a non-drug, noninvasive treatment that can improve ... Therapy (transcranial magnetic stimulation or “TMS”) and Spravato® (esketamine nasal ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

Furthermore, it supported Awakn's expedited regulatory pathway through the 505(b)(2) process, allowing reference to Johnson & Johnson's data on its blockbuster Spravato drug, an esketamine-based ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Spravato has been the subject of much hyperbole since its registration trials first showed that the drug seems to work much more quickly than current antidepressants, with its effects kicking in ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression. Spravato was ...

The new indication allows patients the freedom to choose Spravato as a standalone therapy or alongside existing medications, enabling tailored treatment based on individual needs and tolerability.